The New England Journal of Medicine

Daratumumab or active monitoring for high-risk smoldering multiple myeloma

Journal of Clinical Oncology

Isatuximab subcutaneous by on-body delivery system vs isatuximab intravenous plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Phase 3 IRAKLIA study

Blood and Lymphatic Cancer

An updated indirect comparison of elranatamab versus a real-world external control arm in triple-class refractory multiple myeloma

Current Obesity Reports

Unraveling obesity and multiple myeloma: Insights from epidemiology and molecular mechanisms

Blood Cancer Journal

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: A multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

Bone Marrow Transplantation

Attitudes and perspectives of oncologists about measurable residual disease testing in multiple myeloma: Initiative for standardizing guidelines

Patient Preference and Adherence

Perspectives of healthcare providers and patients with relapsed/refractory multiple myeloma on treatment priorities and novel therapies

Targeted Oncology

Teclistamab dosing in responders: Modeling and simulation results from the MajesTEC-1 study in relapsed/refractory multiple myeloma

JCO Precision Oncology

Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors

Open Forum Infectious Diseases

Outcomes and risk factors for influenza and respiratory syncytial virus lower respiratory tract infections and mortality in patients with lymphoma or multiple myeloma: A 7-year retrospective cohort study